Sanofi

Sanofi-aventis

Katrin Lorenz

Michael Wagner

Torsten Haack

Andreas Evers

Martin Lorenz

Siegfried Stengelin

Dieter Kadereit

Bernd Henkel

Oliver Plettenburg

Martin Bossart

Klaus Wirth

Gerhard Hessler

Laurent Bialy

Klaus Steinmeyer

Joachim Brendel

Jochen Goerlitzer

Olivier Duclos

John Weston

Matthias Loehn

Heinz-Werner Kleemann

Hartmut Strobel

Josef Pernerstorfer

Maria Mendez-Perez

Stefania Pfeiffer-Marek

Alexander Schiffer

Matthias Löhn

Sandrine Biscarrat

Kristin Breitschopf

Li-hsing Wang

Armin Hofmeister

Pradeep K Dhal

James E Stefano

Christian Lange

Thomas Langer

Thomas Olpp

Mark Sommerfeld

Matthias Dreyer

Ralf Elvert

Nino Meyer

Uwe Schwahn

Matthias Lohn

Paul Konowicz

Robert Miller

Magnus Besev

Frederic Jeannot

Christine Rudolph

Werner Dittrich, I

Joseph T Kim

Hans-Peter Nestler

Mark Drew

Fréderic Jeannot

Soraya Hölper

Frédéric Jeannot

Provided herein are FGFR1/KLB targeting agonistic antigen-binding proteins, or fragments thereof, having improved physico-chemical properties. Also provided herein are conjugates comprising an FGFR1/KLB targeting agonistic antigen-binding protein, or a fragment thereof, and at least one GLP-1R agonistic peptide. Further provided are pharmaceutical compositions comprising the antibody (or fragment thereof), or the conjugate provided herein, and the use of the antibody (or fragment thereof), or the use of the conjugate in medicine.

FGFR1/KLB targeting agonistic antigen-binding proteins and conjugates thereof with GLP-1R agonistic peptides

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon agonist linker conjugate Z-L-L-L-Y&#x2014;R, wherein Y represents an GLP-1/Glucagon agonist moiety; and -L is a linker moiety&#x2014;by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon agonist. 

Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate

The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.

Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists

Compounds as peptidic GLP1/glucagon/GIP receptor agonists

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.

Functionalized Exendin-4 derivatives

The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.

Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists

The present invention relates in fused pyrroledicarboxamides of the formula (I), in which R1 to R9, X, m and n are as defined in claims. The compounds of the formula (I) are inhibitors of the acid-sensitive potassium channel TASK-1 and suitable for the treatment of TASK-1 channel-mediated diseases such as arrhythmias, in particular atrial arrhythmias like atrial fibrillation or atrial flutter, and respiratory disorders, in particular sleep-related respiratory disorders like sleep apnea, for example. 

Fused pyrroledicarboxamides and their use as pharmaceuticals

Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists

The present invention relates to compounds of the formula (I), wherein R1, R2, R3, R4 and X have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They are highly potent and selective soluble epoxide hydrolase inhibitors and are suitable, for example, for the therapy and prophylaxis of renal failure, diabetic nephropathy, type 2 diabetes mellitus, cardiovascular diseases, inflammatory diseases or could show beneficial effects in pain, dyslipidemia, atherosclerosis wound healing and stroke. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them. 

Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase

The present invention relates to dual GLP-1/glucagon receptor agonists or optionally trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.

Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4

Dual GLP-1/GIP receptor agonists

Non-acylated exendin-4 peptide analogues

Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists

Functionalized exendin-4 derivatives

The invention relates to substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines of formula (I), their use as medicament, and pharmaceutical preparations comprising them. The compounds of formula (I) act on the TASK-1 potassium channel. The compounds are particularly suitable for the treatment or prevention of atrial arrhythmias, for example atrial fibrillation (AF) or arterial flutter. 

Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-C]pyridines, their use as medicament, and pharmaceutical preparations comprising them

Growing community of inventors

Frankfurt am Main, Germany

Katrin Lorenz